Chris Chlebowski
NESH Alumni Practitioner Directory
Title: Treatment of SARS-CoV2 MRNA injection injuries using isopathic preparations of Aspergillus Niger
Biography
Biography: Chris Chlebowski
Abstract
Introduction: The rollout of the experimental MRNA injections for the treatment of SARS-CoV2 have resulted in a high number of injured patients. Injury types include, but are not limited to, neurological, mast cell activation, reactivation of quiescent infections, gastrointestinal distress, and autoimmune activation and reactivation. As conventional medicine has very little to offer these patients remedies from the natural world must be found to treat and cure these patients. Our clinical observations suggest that the use of commercially available preparations of diluted and potentized Aspergillus Niger resulted in improvement in a large percentage of patients.
Methods: All patients with SARS-CoV2 MRNA experimental injection injuries seen at the Phosphorus Center during a one-year period were enrolled in cohort study. Each patient underwent a comprehensive intake and examination, and when indicated, patients were given a preparation of diluted Aspergills Niger to self-administer at home between regular follow-up visits.
Results: All patients experienced improvement in their primary symptoms as well as marked improvement in ADL’s.
Conclusion: There is a significant decrease in symptoms and improvement in ADL’s in SARS-CoV2 injection injured patients treated with the use of a dilution of Aspergillus Niger. Further studies should be conducted to determine why this compound has utility in the context of injuries from the experimental SARS-CoV2 MRNA injections.